TEJAS-2: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers (clinicaltrials.gov) - Apr 18, 2026 - P2 | N=29 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=90 ➔ 29 | Trial completion date: May 2027 ➔ Feb 2026 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2026 ➔ Feb 2026; Patient recruitment problems.
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Colorectal Cancer • Kidney Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • BRCA • EGFR • FOLR1 • KRAS • MSI
|